Huahai Pharmaceutical: Subsidiary passes on-site inspection by the US FDA.

Hua Hai Pharmaceutical announced that its subsidiary, Hua Hai Technology, underwent an on-site supervision inspection by the US FDA from August 18th to 22nd, 2025, covering the overall quality management system of the factory and oral solid dosage form products. The company recently received a report that the production base of Hua Hai Technology meets the requirements of US drug CGMP and successfully passed the inspection with a VAI result. This inspection provides assurance for the company to expand into international markets, positively impacting core competitiveness and development. However, product sales are subject to uncertainties due to market factors, and investors are reminded to pay attention to risks.